Head Trauma: Towards a new treatment

0
133
NeuroTMULilli

An international collaboration (NeuroTMULille international laboratory) between Taipei Medical University (Ouada Nebie, Thierry Burnouf) and Lille Neuroscience & Cognition (David Blum, David Devos, Luc Buée) just published in the journal “Brain” that the complex pathological consequences of TBI can be alleviated by the delivery of a Human Platelet Lysate (HPL) specifically formulated for brain administration.

The published work demonstrated that HPL improved motor function, mitigated neuroinflammation and oxidative stress in the injured cortical area and reduced synaptic alterations in two mouse models of TBI. “This platelet biotherapy would represent a treatment addressing the multiple physio-pathological causes of TBI and avoid progression towards neurodegenerative processes” David Blum commented on the findings.

HPL are composed of a balanced composition of protective neurotrophic factors with the capacity to activate multiple biological protective pathways and represent a novel therapeutic approach in regenerative medicine. They are prepared from platelet concentrates collected by whole blood donations or apheresis procedures from healthy donors. Platelet concentrates, the source of the human platelet lysates, are essential medicine according to the WHO, and are available worldwide, meeting stringent quality and safety criteria in many countries.

“Our results suggest the importance of a careful formulation of human platelet lysates to ensure optimal safety and efficacy for brain administration. The potential, yet to be confirmed in humans, to deliver this product by the intranasal route opens extremely exciting prospects in the treatment of neurological diseases,” commented Thierry Burnouf.

“The potential, yet to be confirmed in humans, to deliver this product by the intranasal route opens extremely exciting prospects in the treatment of a range of brain neurological diseases. It is now vital to move into further pre-clinical assessment and carefully controlled and monitored clinical studies, ” added Thierry Burnouf.